Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System

NCT06885931 is registered in ClinicalTrials.gov with Amber Therapeutics Ltd as lead sponsor.

NCT NCT06885931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06885931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System
Lead sponsor
Amber Therapeutics Ltd
Phase
Not applicable
Overall status
Recruiting
Start date
June 24, 2025
Completion date
January 31, 2030
Enrollment
86 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pelvic pain, mixed urinary incontinence, stress urinary incontinence (sui), urge urinary incontinence